Sign In
Buy VNDA
$6.09
-0.0400 (-0.653%)
At Close: Jun 03, 2026
After Plunging -7.98% in 4 Weeks, Here's Why the Trend Might Reverse for Vanda (VNDA)
11:18am, Friday, 01'st Sep 2023
The heavy selling pressure might have exhausted for Vanda (VNDA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r
Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023
04:30pm, Thursday, 20'th Jul 2023
Conference Call and Webcast to Follow WASHINGTON , July 20, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2023 o
Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023
06:00pm, Thursday, 27'th Apr 2023
Conference Call and Webcast to Follow WASHINGTON , April 27, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2023 o
Vanda Pharmaceuticals Inc. (VNDA) Q4 2022 Earnings Call Transcript
06:20pm, Wednesday, 08'th Feb 2023
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q4 2022 Earnings Conference Call February 8, 2023 4:30 AM ET Company Participants Kevin Moran - CFO Mihael Polymeropoulos - President, CEO and Chairman Timoth
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023
06:30pm, Wednesday, 01'st Feb 2023
Conference Call and Webcast to Follow WASHINGTON , Feb. 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and ful
Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences
08:30pm, Tuesday, 08'th Nov 2022
WASHINGTON , Nov. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November
Vanda Pharmaceuticals Inc. (VNDA) Q3 2022 Earnings Call Transcript
10:35pm, Wednesday, 02'nd Nov 2022
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Kevin Moran - Senior Vice President & Chief Financial Officer Mihael Polymer
Vanda Pharmaceuticals (VNDA) Lags Q3 Earnings and Revenue Estimates
06:52pm, Wednesday, 02'nd Nov 2022
Vanda (VNDA) delivered earnings and revenue surprises of -40% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
06:00pm, Wednesday, 26'th Oct 2022
Conference Call and Webcast to Follow WASHINGTON , Oct. 26, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on
Vanda: VPO-227 Advancement Signals More Upsides
01:45pm, Tuesday, 25'th Oct 2022
From the commercialization front, Vanda Pharmaceuticals is taking prudent steps to boost Hetlioz and Fanapt sales. The company recently planted long-term growth via the OliPas partnership for ASO deve
Vanda Pharmaceuticals: What The Recent Partnership Entails
04:54pm, Thursday, 06'th Oct 2022
Vanda Pharmaceuticals is a stellar growth stock trading near its cash position. Despite the latest revenue trend aberration, Vanda is still set to post significant sales increase for Fiscal 2022.
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
06:00pm, Thursday, 08'th Sep 2022
WASHINGTON , Sept. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company will participate in the H.C.
The latest meme stock rally is fizzling and speculative buying by retail investors will wane through the rest of 2022, says Vanda
03:40pm, Wednesday, 24'th Aug 2022
The latest meme-stock craze was "doomed to wane" partially because investor sentiment is still predominantly bearish, said Vanda Research.
Vanda Pharmaceuticals (VNDA) Q2 Earnings and Revenues Miss Estimates
06:48pm, Wednesday, 03'rd Aug 2022
Vanda (VNDA) delivered earnings and revenue surprises of -54.55% and 3.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2022 Results - Earnings Call Transcript
06:42pm, Wednesday, 03'rd Aug 2022
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Mihael H. Polymeropoulos - President & Chief Executive Officer Kevin Moran - S
